Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Itama Ranoraya TbkISX:IRRA +1.09%82 Return-on-Tangible-Equity is 7.33% as of Mar. 2026, which is 57% below its 10-year median of 17.01. GuruFocus rates ISX:IRRA with a GF Score™ of 82/100 and a GF Value™ of Rp538.21 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 111 Medical Distribution companies, PT Itama Ranoraya Tbk ranks better than 62.16% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PT Itama Ranoraya Tbk's annualized net income for the quarter that ended in Mar. 2026 was Rp42,772 Mil. PT Itama Ranoraya Tbk's average shareholder tangible equity for the quarter that ended in Mar. 2026 was Rp583,180 Mil. Therefore, PT Itama Ranoraya Tbk's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 7.33%.
The historical rank and industry rank for PT Itama Ranoraya Tbk's Return-on-Tangible-Equity or its related term are showing as below:
ISX:IRRA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 1.1 Med: 17.01 Max: 86.98
Current: 11.83
During the past 10 years, PT Itama Ranoraya Tbk's highest Return-on-Tangible-Equity was 86.98%. The lowest was 1.10%. And the median was 17.01%.
ISX:IRRA's Return-on-Tangible-Equity is ranked better than 62.16% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs ISX:IRRA: 11.83
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
PT Itama Ranoraya Tbk Return-on-Tangible-Equity Related Terms
PT Itama Ranoraya Tbk Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for PT Itama Ranoraya Tbk's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:IRRA vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, PT Itama Ranoraya Tbk's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Itama Ranoraya Tbk Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Itama Ranoraya Tbk's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where PT Itama Ranoraya Tbk's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.33% mean?
PT Itama Ranoraya Tbk (ISX:IRRA) has a Return-on-Tangible-Equity of 7.33% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PT Itama Ranoraya Tbk and its competitors. This is 57% below median its historical median of 17.01. Over the past decade, PT Itama Ranoraya Tbk's Return-on-Tangible-Equity has ranged from 1.10 to 86.98. According to the industry distribution chart, PT Itama Ranoraya Tbk ranks #42 out of 111 companies in the Medical Distribution industry, placing it in the top 37.8%.
Is PT Itama Ranoraya Tbk's Return-on-Tangible-Equity too high?
PT Itama Ranoraya Tbk's current Return-on-Tangible-Equity of 7.33% is 57% below median its 10-year median of 17.01. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 86.98. The Medical Distribution industry median Return-on-Tangible-Equity is 8.81. PT Itama Ranoraya Tbk's value of 7.33% is 16.8% below this industry median. Based on the distribution chart, PT Itama Ranoraya Tbk ranks #42 out of 111 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, PT Itama Ranoraya Tbk has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Itama Ranoraya Tbk's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, PT Itama Ranoraya Tbk ranks #42 out of 111 companies for Return-on-Tangible-Equity. This puts PT Itama Ranoraya Tbk in the upper half of its industry. The industry median Return-on-Tangible-Equity is 8.81. PT Itama Ranoraya Tbk's value of 7.33% is 16.8% below this benchmark. Historically, PT Itama Ranoraya Tbk's own Return-on-Tangible-Equity has ranged from 1.10 to 86.98 over the past decade. While the company's 10-year median is 17.01 vs. the industry median of 8.81, PT Itama Ranoraya Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Itama Ranoraya Tbk's current Return-on-Tangible-Equity of 7.33% is 16.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PT Itama Ranoraya Tbk and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Itama Ranoraya Tbk's current Return-on-Tangible-Equity is 7.33%, which is 57% below median its own 10-year median of 17.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Itama Ranoraya Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Itama Ranoraya Tbk (ISX:IRRA) is currently considered Possible Value Trap. The stock's GF Value™ is Rp538.21, compared to a current price of Rp372.00 — trading 30.9% below its estimated fair value. The current Return-on-Tangible-Equity is 7.33%, which is 57% below median its 10-year median of 17.01 and 16.8% below the Medical Distribution industry median of 8.81. PT Itama Ranoraya Tbk's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For PT Itama Ranoraya Tbk (ISX:IRRA), the current Return-on-Tangible-Equity is 7.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Itama Ranoraya Tbk (ISX:IRRA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Itama Ranoraya Tbk stock appears to be undervalued.
The current stock price of Rp372.00 is trading 30.9% below its estimated GF Value™ of Rp538.21.
GuruFocus considers PT Itama Ranoraya Tbk to be Possible Value Trap.
Key valuation signals for ISX:IRRA:
Return-on-Tangible-Equity: 7.33% (57% below median its 10-year median of 17.01)
GF Value™: Rp538.21 vs. price of Rp372.00 (30.9% below fair value)
Industry Position: 16.8% below the Medical Distribution median (#42 of 111)
No single metric tells the full story. See the ISX:IRRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Itama Ranoraya Tbk focuses on the trade and distribution of medical devices. The company distributes medical devices such as Oneject auto disable syringe, Abbott diagnostics, TerumoBCT, Ortho Clinical diagnostics and others. It business segment includes Vitro Diagnostic Products, Non-Electromedical Sterile Medical Devices, Electromedical Sterile Medical Devices and Other Segments. The key revenue generating segments of the company are In Vitro Diagnostic product.
82GF Score
Get the complete analysis for ISX:IRRA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:IRRA has been successfully added to your 
